Skip to content

US · RDHL · DRUG MANUFACTURERS - SPECIALTY & GENERIC

RedHill Biopharma Ltd. (RDHL) intrinsic value and stock valuation

$0.28as of 2026-11-21 · Mkt cap 1.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

RedHill Biopharma Ltd. DCF and intrinsic value

InvestorsCraft values RDHL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RDHL’s statements →

RedHill Biopharma Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Tel Aviv, TA 6473921 redhillbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$290K-66.1% 5y CAGRd
20112025
Net income
-$-430K
20112025
Free cash flow
-$-9.66M
20112025
Total equity
$4.27M-21% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$290K$8.04M$6.53M$61.8M$85.8M
Operating income-$-7.91M-$-14.61M$12.6M-$-42.84M-$-81.14M
Net income-$-430K-$-8.27M$23.9M-$-71.67M-$-97.74M
EPSd-$-136.08K-$-3.36M$46M-$-597.25M-$-1.09B
Operating cash flow-$-9.65M-$-9.37M-$-35.82M-$-29.18M-$-65.05M
Capital expenditure-$-10K-$-10K-$-10K-$-200K-$-120K
Free cash flow-$-9.66M-$-9.38M-$-35.83M-$-29.38M-$-65.16M
Total assets$25.3M$18M$23.1M$158.9M$181.2M
Total debt$1.07M$360K$1.17M$122.7M$87.8M
Net debt-$-2.9M-$-4.26M-$-4.4M$102.7M$58.3M
Total equity$4.27M-$-4.68M$2.07M-$-48.4M$8.88M
Cash and short-term investments$3.97M$4.62M$6.36M$20M$38M
Income statement
20252024202320222021
Revenue$290K$8.04M$6.53M$61.8M$85.8M
Cost of revenue$0.00$3.19M$3.46M$33.3M$49.4M
Gross profit$290K$4.85M$3.07M$28.5M$36.4M
Research and development expenses$2.02M$1.59M$3.53M$7.28M$29.5M
Selling, general and administrative expenses$6.17M$15.5M$31M$64M$88M
Other expenses$0.00$2.36M-$-44.06M$0.00$0.00
Operating expenses$8.2M$19.5M-$-9.56M$71.3M$117.5M
Cost and expenses$8.2M$22.7M-$-6.1M$104.6M$166.9M
Interest income$20K$130K$90K$140K$50K
Interest expense$20K$60K$370K$41.3M$16.6M
Depreciation and amortization$410K$620K$1.99M$8.15M$18.2M
Ebitda-$-7.65M-$-7.59M$26.3M-$-22.18M-$-63.03M
Operating income-$-7.91M-$-14.61M$12.6M-$-42.84M-$-81.14M
Total other income/expenses, net-$-170K$6.34M$11.3M-$-28.82M-$-16.61M
Income before tax-$-8.08M-$-8.27M$23.9M-$-71.67M-$-97.74M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-430K-$-8.27M$23.9M-$-71.67M-$-97.74M
Weighted average shares outstanding$3.16M$2.46M$520K$120K$90K
Weighted average diluted shares outstanding$3.16M$2.46M$520K$120K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$3.97M$4.62M$6.36M$20M$38M
Net receivables$2.48M$3.57M$3.29M$37.9M$32.5M
Inventory$0.00$3.65M$4.39M$11M$14.8M
Total current assets$6.53M$11.9M$16.1M$85.9M$89.2M
Property, plant and equipment, net$1.1M$440K$1.18M$7.19M$4.22M
Goodwill and intangible assets$5.29M$5.55M$5.58M$65.6M$71.6M
Long-term investments$12.1M$150K$150K$150K$16.2M
Total non-current assets$18.8M$6.13M$6.91M$73M$92M
Total assets$25.3M$18M$23.1M$158.9M$181.2M
Accounts payable$6.42M$7.86M$3.28M$4.23M$11.7M
Short-term debt$170K$710K$1.44M$116.3M$3.24M
Deferred revenue$0.00$0.00$0.00$0.00$37.3M
Total current liabilities$19.2M$22.2M$19.2M$197.5M$81.5M
Long-term debt$900K$0.00$460K$6.44M$86.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.86M$500K$1.74M$9.82M$90.8M
Capital lease obligations$1.07M$360K$1.17M$7.47M$4.19M
Total liabilities$21.1M$22.7M$21M$207.3M$172.3M
Common stock$147.6M$35M$21.4M$2.83M$1.5M
Retained earnings-$-413.75M-$-414.8M-$-407.74M-$-433.86M-$-367.87M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4.27M-$-4.68M$2.07M-$-48.4M$8.88M
Total investments$12.1M$150K$940K$170K$24.7M
Total debt$1.07M$360K$1.17M$122.7M$87.8M
Net debt-$-2.9M-$-4.26M-$-4.4M$102.7M$58.3M
Cash flow statement
20252024202320222021
Net income-$-430K-$-8.27M$23.9M-$-71.67M-$-97.74M
Depreciation and amortization$410K$620K$1.99M$8.15M$18.2M
Stock-based compensation$460K$670K$1.65M$5.67M$10.2M
Change in working capital-$-1.97M$2.05M-$-15.58M$8.01M-$-1.15M
Accounts receivable$2.26M$50K$33.4M-$-2.85M-$-3.02M
Inventory-$-380K$740K$2.38M$3.8M-$-8.29M
Accounts payable-$-440K-$-2.11M-$-950K-$-7.43M$110K
Net cash provided by operating activities-$-9.65M-$-9.37M-$-35.82M-$-29.18M-$-65.05M
Investments in property, plant and equipment-$-10K-$-10K-$-10K-$-200K-$-120K
Acquisitions, net$2M$0.00$0.00$0.00$8.03M
Net cash used for investing activities$1.69M-$-10K$0.00$8.3M-$-8.14M
Common stock issued$7.76M$8.26M$14M$23.8M$78.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.32M$8.42M$21.4M$11.5M$73.5M
Net change in cash-$-650K-$-950K-$-14.4M-$-9.51M$180K
Cash at end of period$3.97M$4.62M$5.57M$20M$29.5M
Operating cash flow-$-9.65M-$-9.37M-$-35.82M-$-29.18M-$-65.05M
Capital expenditure-$-10K-$-10K-$-10K-$-200K-$-120K
Free cash flow-$-9.66M-$-9.38M-$-35.83M-$-29.38M-$-65.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About RedHill Biopharma Ltd.

        RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

        CEO
        Dror Ben-Asher
        Employees
        13
        Beta
        4.97

        Explore

        Frequently asked questions

        What is the intrinsic value of RedHill Biopharma Ltd. (RDHL)?

        InvestorsCraft does not currently publish an intrinsic value for RDHL. How the IC value is calculated.

        Is RDHL undervalued?

        InvestorsCraft does not publish an undervaluation signal for RDHL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.